NBS-C  BioScience 
News & Milestones 



April, 2016:

NBS-C BioScience signs  a CRO Frame Contract with Mosaic Biomedicals SL, Barcelona, Spain, to accompany development of a novel therapeutic monoclonal antibody through all pre-clinical stages, establish a GxP validated SPR based identity / potency assay for clinical sample measurement and batch release during clinical development phases.

 
June, 2015:

Publication of patent application PCT/EP2014/077937, disclosing a new chemical compound for treatment of neuropathic pain and other disorders, displaying a novel mode of action discovered in collaboration of NBS-C BioScience with NovAssay SA, Switzerland


May, 2014:

Key data generated at NBS-C BioScience during a research cooperation with the  Institute of Molecular Biotechnology, Vienna (IMBA)  are published in Nature 511, 104-107

March, 2013:


NBS-C BioScience and Fresenius Kabi, Germany, sign a five year CRO frame contract


February 2013:

NBS-C BioScience and Harvard Medical School, Children‘s Hospital, initiate collaboration

January, 2013:

The service level contract with Baxter Innovations is prolonged for another two year period

November 2011:

NBS-C BioScience signs a two year service level contract with Baxter Innovations Austria


July 2011:

NBS-C BioScience moves into its new location at the site of the partner company Vela Laboratories, located in Vienna, Brunnerstrasse 69. This merger of company sites opens a wide field of intensified synergies of mutual benefit.

May 2011:

NBS-C BioScience successfully completes its research project "Anti-Idiotype Vaccine for IgE induced Diseases" by achieving all pre-defined milestones, demonstrating Proof of Strategic Concept and generating two protective prototype immunogens with the potential to be developed as anti-allergy vaccine.

April 2010

NBS-C BioScience signs a partnership agreement with
Vela Laboratories, a Viennese GMP-certified contract laboratory offering protein characterisation services (Biopharmaceuticals, Biologics, Biogenerics / Biosimilars) in all stages of product development (pre-clinical, clinical) up to market approval. This agreement provides a platform for mutual project exchange and collaboration, thus opening access to a fully functional GxP environment for NBS-C BioScience projects.

March 2010

NBS-C BioScience wins the third price of the science 2business award. For the fourth time the science2business award was presented by the Austrian Ministery of Economics, Family and Youth for the best and most creative cooperations between industry and science. 27 applicants with 175 cooperation partners from 12 nations participated in the competition. More...


March 2010


Together with GE Healthcare, NBS-C BioScience organizes the 1st Vienna Biacore / MicroCal User Day on March 16th, 2010, at the NBS-C BioScience site located at the  Biotech Competence Center in Vienna. The purpose of the meeting was to bring together experienced users and researchers interested in  the field of surface plasmon resonance and microcalorimetry as versatile tools for studying the biophysical characteristics of molecular interactions. More...


November 2009

NBS-C obtains worldwide exclusive license to manufacture and sell monoclonal antibodies and other recombinant proteins originating from the Institute of Immunology, University Bern, Switzerland, to be developed and brought to market as Allergy Research Tools and Diagnostics.

September, 2009

Prof. Beda M. Stadler, Director of the Institute of Immunology, University Bern, Switzerland, joins as Scientific Advisor.


January, 2009

NBS-C BioScience & Consulting GmbH is founded by a group of scientists from Novartis Institutes for BioMedical Research, Vienna, AT, and Horsham, UK. Initiation of t
he project "Anti-Idiotype Vaccine for IgE Induced Diseases", first price winner of call CoOperate 08, funded by Zentrum für Innovation und Technologie (ZIT), Vienna.